



April 30, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of Establishment Inspection Report from the U.S. FDA for the Company's Pithampur Unit-1, India facility. Inspection for the said facility was conducted by the U.S. FDA between February 3, 2020 and February 11, 2020 and concluded with two observations.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

RAJVARDH
AN VISHNU
SATAM

Digitally signed by RAJVARDHAN VISHNU
SATAM
DN: cn=RAJVARDHAN VISHNU
SATAM, postalCode=400062, st=Maharashtra,
2.5.4.20=c19d8ef961d98a59e973a093a4d
3924b2532eb29f96ea7e2abed74700f537
5b7,
serialNumber=d8be60a88c796663c738
e025a5e0b475d195726c8b07a2809c424
2771b2a, cn=RAJVARDHAN VISHNU
SATAM
Date: 2020.04.30 08:37:18 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl- : a/a.

Lupin's Pithampur Unit-1 facility receives EIR from U.S. FDA

Mumbai, India, April 30, 2020: Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Pithampur Unit-1, India facility. The inspection for the facility was conducted by the U.S. FDA between February 3, 2020 and February 11, 2020 and concluded with two observations.

Commenting on the receipt of the EIR, **Nilesh Gupta, Managing Director, Lupin** said, *"We are very happy to have received the EIR for our Pithampur Unit-1 facility with Voluntary Action Indicated (VAI) status. Continuous improvement of our quality and compliance standards across all our manufacturing sites is a key focus area for the company and we are committed to work with the U.S. FDA to manufacture and supply products of the highest quality from all our manufacturing sites."*

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and Corporate Communications

Email: arvindbothra@lupin.com

Tel: +91 22 6640 8237

Manjira Sharma

General Manager – Corporate Communications

Email: manjirasharma@lupin.com

Tel: +91 22 6640 2532